摘要
目的探讨甲苯磺酸索拉非尼联合经肝动脉化疗栓塞术(TACE)用于不可切除的局限性肝癌患者的疗效。方法选取不可手术切除的肝癌患者为研究对象,随机分为对照组和观察组,观察组给予甲苯磺酸索拉非尼联合TACE治疗,对照组行单纯TACE治疗。比较2组患者临床疗效、肿瘤标志物[甲胎蛋白(AFP)、糖类抗原(CA19-9)]水平、肝功能指标[谷丙转氨酶(ALT)、总胆红素(TBil)、白蛋白(Alb)]水平及不良反应发生率。结果对照组客观缓解率为33.33%,观察组客观缓解率为54.17%,差异有统计学意义(P<0.05);对照组疾病控制率为62.50%,观察组患者疾病控制率为87.50%,差异有统计学意义(P<0.05)。观察组患者AFP、CA19-9水平、ALT、TBil和Alb水平均显著低于对照组,差异均有统计学意义(P<0.05)。2组不良反应发生率差异无统计学意义(P>0.05)。结论甲苯磺酸索拉非尼片联合TACE术用于不可手术切除的局限性肝癌患者具有更好的临床疗效,对肝功能的损伤较小,且不增加不良反应,较为安全可靠。
Objective To investigate the efficacy of sorafenib toluene sulfonate combined with transcatheter arterial chemoembolization(TACE)in patients with unresectable localized liver cancer.Methods Patients with unresectable localized liver cancer were selected as the research objects.They were randomly divided into the control group and the observation group.The observation group was treated with sorafenib toluene sulfonate combined with TACE,and the control group was treated with TACE alone.The clinical efficacy,the level of tumor markers[alpha fetoprotein(AFP),carbohydrate antigen(CA19-9)],the level of liver function indicators[alanine aminotransferase(ALT),total bilirubin(TBIL),albumin(ALB)]and the incidence of adverse reactions were compared between the 2 groups.Results The objective remission rate was 33.33%in the control group and 54.17%in the observation group,the difference was statistically significant(P<0.05).The disease control rate was 62.50%in the control group and 87.50%in the observation group,the difference was statistically significant(P<0.05);The levels of AFP,CA19-9,ALT,Tbil and Alb in the control group were significantly lower than those in the control group(P<0.05).Adverse reaction of the 2 groups had no statistical difference(P<0.05).Conclusion Sorafenib tosylate combined with TACE has a better clinical effect in patients with unresectable localized liver cancer,with less damage to liver function and no increase in adverse reactions,which is safer and more reliable.
作者
朱九荣
岳恺
叶亚平
吴玉卓
ZHU Jiurong;YUE Kai;YE Yaping(Nanyang Central Hospital,Nanyang,473000)
出处
《实用癌症杂志》
2024年第4期648-651,677,共5页
The Practical Journal of Cancer
关键词
甲苯磺酸索拉非尼
经肝动脉化疗栓塞术
局限性肝癌
肝功能
临床疗效
Sorafenib toluene sulfonate
Transcatheter hepatic arterial chemoembolization
Localized liver cancer
Liver function
Clinical efficacy
